A new partnership will integrate Pearl’s Second Opinion disease detection platform with Planmeca’s Romexis imaging software. Note: This product does not yet have a release date in North America
Artificial intelligence (AI) company Pearl, and dental equipment manufacturer Planmeca, have announced a new partnership that will integrate Pearl’s Second Opinion® disease detection platform with Planmeca’s imaging software, Planmeca Romexis®.
“AI is primed to revolutionize the global dentistry market, and together with Planmeca Romexis, we’re expanding access to the powerful capabilities of this technology,” Ophir
Tanz, founder and CEO of Pearl, said according to a press release from the company. “Our partnership with Planmeca will seamlessly integrate Second Opinion into one of the most popular, powerful, and technologically advanced imaging platforms in dentistry, streamlining clinical efficiencies and steering the industry towards a fully AI-powered future.”
Second Opinion is said to be the first AI software with clearances to help dentists detect a variety of common oral conditions in bitewing, periapical, and panoramic x-rays of adult teeth in patients as young as 12 years old. Planmeca users will be able to utilize Pearl’s AI technology to evaluate x-ray images directly within the Romexis platform. This is said to streamline patient communication and offer enhanced diagnostic capabilities, according to the press release. This integration will be available for all Romexis users soon.
“We are deeply committed to delivering the most advanced capabilities in digital imaging to dental clinics of all sizes and specialties,” said Helianna Puhlin-Nurminen, vice president of digital imaging and applications at Planmeca. “This collaboration with Pearl will further augment diagnostic consistency, accuracy, and transparency in dental care, equipping Romexis users with the most advanced pathology detection and patient communication technology.”
Editor's Note: This product does not yet have a release date in North America